BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 8, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» Seed financing at Isomab to fund lead antibody for peripheral arterial disease
To read the full story,
subscribe
or
sign in
.
Cardiovascular
Seed financing at Isomab to fund lead antibody for peripheral arterial disease
Feb. 21, 2024
No Comments
Isomab Ltd has closed a £7.5 million (US$9.4 million) seed financing round. The company is developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases with an initial focus on peripheral ischemia.
BioWorld Science
Cardiovascular
Antibody
Seed